Invitae - News & Events - Press releases

December 31, 2019 Invitae to Present at the 38th Annual J.P. Morgan Healthcare Conference

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that Sean George, co-founder and chief executive officer of Invitae, will present at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020 at 7:30 a.m. Pacific at the Westin St. Francis in San Francisco. Following the company presentation, management will participate in a breakout session at 8:00 a.m. Pacific. The live webcast of both the presentation and the breakout session may be accessed by visiting the investors section of the company's website at ir.invitae.com . A replay of the webcasts will be available shortly after the conclusion of the presentation and breakout session. About Invitae Invitae Corporation (NYSE: NVTA) is a leading medical genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service

December 10, 2019 Invitae Announces Program with BioMarin to Expand Access to Genetic Testing for Skeletal Dysplasias

-Genetic testing can identify causes of rare disorders that affect bone growth and development in children- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the launch of Discover Dysplasias™ , an initiative with BioMarin Pharmaceutical to offer genetic testing at no charge to patients who show signs or symptoms of having a skeletal dysplasia, a group of rare, mostly genetic disorders that affect bones and joints and impact growth and development in children. "There are hundreds of different types of skeletal dysplasia, many with similar clinical features. If left untreated, patients can experience a variety of serious consequences, such as developmental delay, as well as serious spinal and joint problems," said Robert Nussbaum, M.D., chief medical officer of Invitae. "By identifying the genetic cause of the disease earlier, clinicians can get children on a treatment plan specific to their precise condition sooner, which could help avoid or delay the most

November 21, 2019 Invitae to Participate in the 31st Annual Piper Jaffray Healthcare Conference

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that Shelly Guyer, chief financial officer of Invitae, will participate in a fireside chat at the 31st Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2019 at approximately 10:00 a.m. Eastern / 7:00 a.m. Pacific in New York City. The live, listen-only webcast may be accessed by visiting the investors section of the company's website at ir.invitae.com . A replay of the webcast will be available shortly after the conclusion of the fireside chat and will be archived on the company's website. About Invitae Invitae Corporation (NYSE: NVTA) is a leading medical genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. For more information, visit the

November 15, 2019 Invitae Launches Invitae Discover Research Platform on Apple Watch; First Study on Platform Will Investigate Genetic Causes of Cardiovascular Disease

-Study announced in conjunction with American Heart Association's Scientific Sessions-
-Researchers also presenting data on limitations of highly targeted screening strategies in familial hypercholesterolemia- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced Invitae Discover , a clinical research platform that leverages biometric data available through Apple Watch to provide better understanding of the genetic causes of disease. The first study on the platform will evaluate genetics in cardiovascular disease and was announced in conjunction with the American Heart Association's Scientific Sessions where researchers are presenting data on genetic screening in familial hypercholesterolemia. "The creation of the Invitae Discover platform will make it easier to conduct studies that assess genetic test results alongside the biometric data that is now easily available on Apple Watch, thereby joining basic electrophysiological data with genetic

November 11, 2019 Invitae to Acquire Clear Genetics

-Clear Genetics provides scalable patient support solutions to meet rapidly expanding medical genetics market-
-Clinician-designed chatbots make it easier for patients to access medically responsible, actionable genetic testing- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced it has entered into a definitive agreement to acquire Clear Genetics, a leading developer of software for providing genetic services at scale. Using intuitive chatbots, Clear Genetics equips patients with actionable information throughout the genetic testing process and provides guidance for understanding test results. The acquisition will further expand Invitae's ability to scale and deliver genetic information as a part of routine medical care. "For genetics to truly go mainstream, patients and clinicians need automated workflow solutions like those Clear Genetics has created," said Sean George, co-founder and chief executive officer of Invitae. "In working with the

November 6, 2019 Invitae Reports $56.5 Million in Quarterly Revenue Driven by 129,000 Samples

- Increased quarterly revenue by 51% and volume by 65% year-over-year -
- Now in network with Cigna, all major payers with approximately 295 million covered lives -
- Hosting conference call and webcast today at 4:30pm Eastern/1:30pm Pacific - Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the third quarter ended September 30, 2019. "With our 26 th consecutive quarter of dynamic growth, we continue to demonstrate our ability to grow the business while investing in the technologies necessary to drive the transformation of genetics," said Sean George, co-founder and chief executive officer of Invitae. "Based on how we are tracking toward our guidance and our demonstrated ability to take share and more importantly expand the market, we believe that we are driving forward as the clear leader in offering comprehensive, medical genetic information at affordable prices access all stages of life."

November 5, 2019 Invitae Highlights Importance of Medical Genetics, Honors Excellence in Genetic Counseling at National Society of Genetic Counselors (NSGC) 38th Annual Conference

Researchers from Invitae Corporation (NYSE: NVTA), a leading medical genetics company, are presenting research this week at the National Society of Genetic Counselors (NSGC) 37th Annual Conference in Atlanta that helps push forward the science and practice of genetics in patient care. In addition to its research presentations, the company is supporting the Code Talker award, which recognizes excellence in the field of genetic counseling. The company's wide-ranging research presentations, which include plenary, platform and poster presentations, add to both the science and practice of the fast-growing field of medical genetics. Among the company's presentations are studies highlighting the potential of genetic testing to increase early diagnosis of pediatric epilepsy, along with presentations underscoring the importance of high quality medical genetic testing and genetic counseling services as consumer use of genetic health screening continues to grow. In addition to addressing current

October 23, 2019 Invitae to announce third quarter 2019 financial results on November 6, 2019

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its third quarter 2019 financial results on Wednesday, November 6, 2019 and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights. The dial-in numbers for the conference call are (866) 393-4306 for domestic callers and (734) 385-2616 for international callers, and the reservation number for both is 9085356. The live webcast of the call and slide deck may be accessed by visiting the investors section of the company's website at ir.invitae.com . A replay of the webcast and conference call will be available shortly after the conclusion of the call and will be archived on the company's website. Following prepared remarks, management will respond to questions from investors and analysts, subject to time limitations. We encourage our shareholders and those representing them to send in questions

October 17, 2019 Research presented by Invitae at the American Society of Human Genetics Meeting Pushes Science and Practice of Genetics Forward

- Advances in classification, new approaches to genetics in cancer and implications of primary and secondary findings for clinical care among wide-ranging data presentations - Researchers from Invitae Corporation (NYSE: NVTA), a leading medical genetics company, are presenting data showing the increasing utility of genetic information at the American Society of Human Genetics (ASHG) annual meeting this week, ranging from comprehensive screening for cancer patients, to appropriate clinical follow up for women using non-invasive prenatal screening, to the limitations of direct to consumer genetic screening health reports. The company's research includes three platform presentations and multiple poster sessions, many performed in collaboration with leading academic researchers. Among the data presented is a study evaluating the utility of combined germline testing and tumor profiling (somatic testing) in cancer patients. Germline and somatic testing are increasingly used in precision

September 9, 2019 Invitae Expands Detect Program to Offer No-Charge Genetic Testing to Pancreatic Cancer Patients

- Professional guidelines recommend genetic testing for all pancreatic cancer patients -
- Detect sponsored testing programs are designed to overcome barriers to testing and connect patients to earlier diagnosis and treatments - Invitae (NYSE: NVTA), a leading medical genetics company, today announced the availability of Detect Hereditary Pancreatic Cancer, a testing program that offers no-charge genetic testing and counseling to patients with pancreatic cancer. Genetic testing is recommended by clinicians for all pancreatic cancer patients to guide treatment choices and evaluate eligibility for clinical trials. "Genetic information can be particularly valuable for people with pancreatic cancer, even though many of them will be diagnosed with advanced disease. For these patients, having access to information about genetic changes may help identify precision therapies or a clinical trial opportunity," said Robert Nussbaum, M.D., chief medical officer of Invitae. "We know that the

September 6, 2019 Invitae Prices Upsized Offering of $300 Million of Convertible Senior Notes

Invitae Corporation (NYSE: NVTA) announced the pricing on September 5, 2019 of $300.0 million aggregate principal amount of 2.00% convertible senior notes due 2024 (the "notes") in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The aggregate principal amount of the offering was increased from the previously announced offering size of $200.0 million. Invitae granted the initial purchasers of the notes a 13-day option to purchase up to an additional $50.0 million principal amount of notes on the same terms and conditions. The sale of the notes is scheduled to close on September 10, 2019, subject to the satisfaction of customary closing conditions. Invitae estimates that the net proceeds from the offering of the notes will be approximately $291.2 million (or $339.8 million if the initial purchasers exercise their option to purchase additional notes in full), after deducting the initial

September 4, 2019 Invitae Announces Proposed Offering of $200 Million of Convertible Senior Notes

Invitae Corporation (NYSE: NVTA) today announced its intention to offer, subject to market conditions and other factors, $200.0 million aggregate principal amount of convertible senior notes due 2024 (the "notes") in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). In connection with the offering, Invitae expects to grant the initial purchasers of the notes a 13-day option to purchase up to an additional $30.0 million principal amount of notes on the same terms and conditions. Invitae intends to use the net proceeds from the offering of the notes to repay, including a prepayment premium, the $75.0 million in aggregate principal amount of notes outstanding under its 2018 Note Purchase Agreement and for international expansion, infrastructure investment, working capital and other general corporate purposes. Invitae may also use a portion of the net proceeds from the offering to acquire or

August 6, 2019 Invitae Reports $53.5 Million in Quarterly Revenue Driven by More Than 111,000 Samples in Quarterly Volume

- Increased quarterly revenue by 43% and volume by 52% year-over-year -
- Announced appointment of Sean George as chairman of the Board of Directors, retirement of Randy Scott as executive chairman, effective September 1, 2019 -
- Hosting conference call and webcast today at 4:30pm Eastern/1:30pm Pacific - Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the second quarter ended June 30, 2019. "We have now delivered our 25th quarter of impressive growth in both revenue and volume, while continuing to invest in new technologies that further our position as a leader in the rapidly evolving genetics industry," said Sean George, co-founder and chief executive officer of Invitae. "We are beginning to stand out to our customers as the company that offers the most comprehensive menu of high-quality, affordable genetic testing to everyone who can benefit, enabling us to bring genetics more broadly into

July 24, 2019 Invitae Launches Detect Programs to Make it Easier for Patients to Get Genetic Testing for Prostate Cancer, Muscular Dystrophy and Heart Conditions

- Designed to overcome barriers to testing and connect patients to earlier diagnosis and treatments -
- Targeting diagnosis of muscular dystrophy, prostate cancer, cardiomyopathy and arrhythmia and lysosomal storage diseases - Invitae (NYSE: NVTA), a leading medical genetics company, today announced the availability of its Detect programs to provide no-charge genetic testing for conditions in which testing is underutilized and can improve diagnosis and treatment. Research has shown no-charge testing programs result in earlier diagnosis and treatment. Enrollment is now open for Detect programs in four conditions: muscular dystrophy, prostate cancer, cardiomyopathy and arrhythmia and lysosomal storage diseases. "Helping remove or reduce cost as a barrier and enabling faster, accurate diagnosis is critical for families searching for answers and navigating what can be a diagnostic odyssey," said Kristin Stephenson, Chief Advocacy & Care Services Officer of the Muscular Dystrophy

July 23, 2019 Invitae to announce second quarter 2019 financial results on August 6, 2019

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its second quarter 2019 financial results on Tuesday, August 6, 2019 and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights. The dial-in numbers for the conference call are (866) 393-4306 for domestic callers and (734) 385-2616 for international callers, and the reservation number for both is 6153749. The live webcast of the call and slide deck may be accessed here or by visiting the investors section of the company's website at ir.invitae.com . A replay of the webcast and conference call will be available shortly after the conclusion of the call and will be archived on the company's website. Following prepared remarks, management will respond to questions from investors and analysts, subject to time limitations. We encourage our shareholders and those representing them to send in

July 11, 2019 Invitae to Acquire Jungla to Advance Genetic Variant Interpretation, Adds Supplemental RNA Analysis to Deliver Deeper, More Informative Results to Patients

- Jungla Applies Advanced Modeling Technologies, Including Artificial Intelligence, to Enhance Scalable Genetic Variant Interpretation -
- Invitae Now Using Supplemental RNA Analysis to Enhance Genetic Variant Interpretation in Cancer Testing - Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced it has entered into a definitive agreement to acquire Jungla Inc. , a privately held company funded by Andreessen Horowitz (a16z) that has developed a cloud-based platform that combines clinical knowledge with advances in functional genomics, biophysics, cellular engineering, machine learning, and distributed systems to help clinicians and patients understand the results of genetic and genomic tests. The combination is expected to further enhance Invitae's genetic variant interpretation and ability to deliver high-quality, more affordable genetic testing for use in mainstream medical care. Separately, Invitae announced the addition of RNA analysis to its

June 20, 2019 Invitae Reports Inducement Grants Under NYSE Rule 303A.08 to Former Employees of Singular Bio, Inc. in Connection with Closing of Acquisition

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it granted time-based and development milestone-based restricted stock units ("RSUs") to new employees who joined Invitae in connection with its acquisition of Singular Bio, Inc. The RSUs were granted under Invitae's 2015 Stock Incentive Plan, which was amended and restated to create an additional pool of shares of Invitae common stock to be used exclusively for the grant of inducement awards in compliance with New York Stock Exchange Rule 303A.08 ("Rule 303A.08"). The RSUs were approved by the Board of Directors of Invitae and were made as an inducement material to each employee entering into employment with Invitae in reliance on the employment inducement exemption under Rule 303A.08. On June 20, 2019, Invitae granted RSUs having a value of up to $90 million to eight former employees of Singular Bio who became employees of Invitae following its acquisition of Singular Bio, including Hywel

June 17, 2019 Invitae to Acquire Singular Bio to Help Increase Access to Genetic Screening in Early Pregnancy

- Singular Bio's Technology Designed to Enable High-Quality, Low-Cost Genetic Testing at Scale to Expand Access to Non-Invasive Prenatal Screening - Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced it has entered into a definitive agreement to acquire Singular Bio , Inc., a privately held company developing single molecule detection technology that enables lower costs and expanded use of high-quality, cell-free, nucleic acid analysis, initially for application in non-invasive prenatal screening (NIPS). "Since we began, Invitae has invested deeply to harness the power of the most advanced genetic testing technologies in order to deliver expert-level genetic information at scale, and bringing this company into Invitae is the next step in that process," said Sean George, PhD, co-founder and chief executive officer of Invitae. "Singular Bio is building an approach to non-invasive prenatal screening with the potential to achieve the cost savings

June 12, 2019 Invitae Announces ID YOUR IRD Program to Expand Access to Genetic Testing for Inherited Retinal Disorders

-Genetic testing can identify causes of rare, progressive eye disorders- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the launch of ID YOUR IRD, an initiative with Spark Therapeutics to offer genetic testing at no charge to patients suspected by their healthcare providers of having an inherited retinal disease (IRD), a group of rare, progressive eye disorders that may result in vision loss or blindness and are caused by inherited genetic changes. "Identifying the genetic cause of an inherited retinal disease can not only provide an accurate genetic diagnosis, but also help patients and clinicians make more informed decisions about their care, including considering gene-specific clinical trial options," said Robert Nussbaum, MD, chief medical officer of Invitae. "These degenerative diseases can cause severe visual impairment, up to and including blindness, often in children. We are pleased to collaborate with Spark Therapeutics on this program to increase

June 3, 2019 Invitae introduces new service to make it easier for consumers to receive the medical genetic testing that experts trust

- Provides high-quality, affordable, clinician-guided genetic testing to inform healthcare decisions -
- Partnering with patient advocacy organizations to make testing more available to those who need it - Invitae (NYSE: NVTA), a leader in medical genetics, today announced the availability of its new service for consumers, which makes it easier for consumers to order and receive the same high-quality, medical genetic testing from Invitae that experts use and trust. The service provides affordable testing along with guidance from a network of trained clinicians to help consumers get health information they can act on. The company made the announcement at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. "Even as availability of recreational genetic tests has exploded, the roadblocks to getting medical genetic testing that can be used to make health decisions remain. Our intent is to create a new, medically responsible model that makes it easier for

May 31, 2019 Research from Invitae Demonstrates the Importance of Germline Multigene Panel Testing in Guiding Therapy for Expanding Groups of Cancer Patients

- Data to be presented at the American Society of Clinical Oncology Annual Meeting -
- Underscores importance of genetic testing to guide precision medicine treatment and improve family screening - Researchers from Invitae (NYSE: NVTA), a leading medical genetics company, will present data that underscore the clinical utility of comprehensive genetic information for patients with breast, colorectal, prostate and pancreatic cancer to inform treatment decisions. Among the data, researchers will discuss findings showing that multigene germline genetic testing for breast cancer patients impacts patient outcomes and informs surgical strategy, precision medicine treatment and clinical trial eligibility. The studies will be presented at the American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago, which starts today. A study of breast cancer patients conducted with researchers from the TME Breast Care Network, a network of more than 300 leading breast cancer physicians,

May 22, 2019 Invitae to Present at the 2019 William Blair Growth Stock Conference

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that Sean George, co-founder and chief executive officer of Invitae will present at the 2019 William Blair Growth Stock Conference on Wednesday, June 5, 2019 at 2:40 p.m. Central / 12:40 p.m. Pacific in Chicago. A live webcast of the presentation may be accessed by visiting the investors section of the company's website at ir.invitae.com . A replay of the webcast will be available shortly after the conclusion of the presentation and will be archived on the company's website. About Invitae Invitae Corporation (NYSE: NVTA) is a leading medical genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. For more information, visit the company's website at invitae.com . Source:

May 15, 2019 Invitae to Present at the UBS Global Healthcare Conference

Invitae Corporation (NYSE: NVTA), the leader in advanced medical genetics, today announced that Sean George, co-founder and chief executive officer of Invitae, will present at the UBS Global Healthcare Conference on Wednesday, May 22, 2019 at 10:30 a.m. Eastern / 7:30 a.m. Pacific in New York City. A live webcast of the presentation may be accessed by visiting the investors section of the company's website at ir.invitae.com . A replay of the webcast will be available shortly after the conclusion of the presentation and will be archived on the company's website. About Invitae Invitae Corporation (NYSE: NVTA) is the leading advanced medical genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. For more information, visit the company's website at

May 7, 2019 Invitae Reports 47% Growth in Quarterly Revenue and Volume Year-Over-Year

- On track to deliver more than 500,000 test samples and more than $220 million in revenue in 2019 -
- Signed eight new biopharma partnerships in the quarter, expanding the breadth of the genome network -
- Management hosting conference call and webcast today at 4:30pm Eastern/1:30pm Pacific - Invitae Corporation (NYSE: NVTA), the leader in advanced medical genetics, today announced financial and operating results for the first quarter ended March 31, 2019. "We've seen another first quarter of foundational growth across all of our customer segments, with strong momentum putting us well on our way to exceed our 2019 guidance and in 2020 to serve more than one million patients with more than $500 million in revenue," said Sean George, co-founder and chief executive officer of Invitae. "Invitae is rapidly becoming the preferred provider of genetic information for clinicians and biopharma partners and increasingly the partner of choice for third party commercial payers

May 3, 2019 New Study From Invitae Highlights the Importance of Multigene Genetic Testing for Uterine Cancer Patients

Results from one of the largest datasets in uterine cancer presented at The American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting Researchers from Invitae (NYSE: NVTA), a leading genetics company, will present a study of more than 6,500 patients with uterine cancer showing that genetic testing provided more than 80 percent of patients with information that made them eligible for precision medicine therapies. The study also highlighted the importance of multigene panel testing versus traditional, limited approaches and was presented this week at the 2019 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting. "Genetic testing for uterine carcinoma has traditionally been limited to a very targeted number of genes that have an association with uterine cancer," said Robert Nussbaum, M.D., chief medical officer of Invitae and one of the authors of the study. "This study revealed that such limited testing

April 23, 2019 Invitae to announce first quarter 2019 financial results on May 7, 2019

Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced that it will report its first quarter 2019 financial results on Tuesday, May 7, 2019 and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights. The dial-in numbers for the conference call are (866) 393-4306 for domestic callers and (734) 385-2616 for international callers, and the reservation number for both is 3435689. Following prepared remarks, management will respond to questions from investors and analysts, subject to time limitations. We encourage our shareholders and those representing them to send in questions to ir@invitae.com . The live webinar of the call may be accessed by visiting the investors section of the company's website at ir.invitae.com. A replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company's website. About Invitae Invitae Corporation

April 2, 2019 Research Underscores Need for Updated Guidelines to Include Multigene Testing for Cancer Patients

- Data presented at The American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting - Researchers from Invitae (NYSE: NVTA), a leading genetics company, will present data from more than 113,000 patients that support updating genetic testing guidelines to include clear recommendations for multigene panel testing in patients with cancer. According to the study, patients with ovarian, breast, pancreatic, prostate and colorectal cancer with potentially actionable germline variants are being missed each year when clinicians adhere to guidelines that restrict testing to one or a few gene panels. The study is among the company's data presented this week at the 2019 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting in Seattle. "Genetic test panels that include just a few of the clinically important genes provide incomplete genetic information for patients and their clinicians, both in terms of informing treatment choices

March 14, 2019 Invitae to Present at the Oppenheimer 29th Annual Healthcare Conference

Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced that Sean George, co-founder and chief executive officer of Invitae, will present at the Oppenheimer 29th Annual Healthcare Conference on Wednesday, March 20, 2019 at 1:35 p.m. Eastern / 10:35 a.m. Pacific in New York City. A live webcast of the presentation may be accessed by visiting the investors section of the company's website at ir.invitae.com . A replay of the webcast will be available shortly after the conclusion of the presentation and will be archived on the company's website. About Invitae Invitae Corporation (NYSE: NVTA) is a leading genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. For more information, visit the company's website at invitae.com. Contact:

March 6, 2019 Invitae Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares of Common Stock

Invitae Corporation (NYSE: NVTA) today announced the exercise in full of the underwriters' option to purchase an additional 1,350,000 shares of its common stock at the public offering price of $19.00 per share, in connection with Invitae's recently announced underwritten public offering of 9,000,000 shares of its common stock. As a result of the underwriters' option exercise, the aggregate gross proceeds to Invitae from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $196.7 million. The offering is expected to close on or about March 8, 2019, subject to the satisfaction of customary closing conditions. J.P. Morgan Securities LLC, Cowen and Company, LLC and SVB Leerink LLC are acting as the book-running managers for the offering. An automatic shelf registration statement relating to the shares was filed with the Securities and Exchange Commission and became effective on March 4, 2019. A copy of the

March 5, 2019 Invitae Announces Pricing of Public Offering of Common Stock

Invitae Corporation (NYSE: NVTA) today announced the pricing of an underwritten public offering of 9,000,000 shares of its common stock at a price to the public of $19.00 per share. All of the shares are being sold by Invitae. The gross proceeds to Invitae from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be $171.0 million. The offering is expected to close on or about March 8, 2019, subject to customary closing conditions. In addition, Invitae has granted the underwriters a 30-day option to purchase up to an additional 1,350,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. J.P. Morgan Securities LLC, Cowen and Company, LLC and SVB Leerink LLC are acting as the book-running managers for the offering. An automatic shelf registration statement relating to the shares was filed with the Securities and Exchange Commission and became effective on March 4, 2019.

March 4, 2019 Invitae Announces Proposed Public Offering of Common Stock

Invitae Corporation (NYSE: NVTA) today announced that it has commenced an underwritten public offering of $125.0 million of shares of its common stock, before deducting underwriting discounts and commissions and other offering expenses. All of the shares are being offered by Invitae. In addition, Invitae expects to grant the underwriters a 30-day option to purchase up to an additional $18.75 million of shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. J.P. Morgan Securities LLC, Cowen and Company, LLC and SVB Leerink LLC are acting as the book-running managers for the offering. An automatic shelf registration statement relating to the shares was filed with the Securities and Exchange Commission and became effective on March 4, 2019. A copy of the

February 26, 2019 Behind the Seizure™ Program Expansion Helps Speed the Diagnosis of Genetic Epilepsy in Younger Children Experiencing Unprovoked Seizures

-Stoke Therapeutics and Xenon Pharmaceuticals Join Founders BioMarin and Invitae to Offer a No-Cost Epilepsy Gene Panel Testing Program for Children Up to 60 Months Who Have Had an Unprovoked Seizure- As Rare Disease Day focuses attention on the challenges of diagnosing rare, often genetic conditions, BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Invitae Corporation (NYSE: NVTA), Stoke Therapeutics and Xenon Pharmaceuticals (NASDAQ: XENE) today announced the expansion of Behind the Seizure , an innovative, cross-company collaboration that aims to provide faster diagnosis for young children with epilepsy. Previously available to patients ages 2-4 years, the program will expand eligibility to make no-cost genetic testing available for healthcare providers to order for children who have had an unprovoked seizure from birth up to age five (0 to 60 months). "Genetic testing can be invaluable in helping families and healthcare providers better understand how to care for children living with

February 19, 2019 Invitae More Than Doubles Annual Volume and Revenue Year-Over-Year, Delivering 117% in Revenue Growth Driven by 102% Growth in Volume in 2018

- Annual volume, revenue exceed increased guidance for full-year 2018 -
- Guided to more than 500,000 test samples, $220 million in revenue expected in 2019 -
- Management hosting conference call and webcast today at 4:30pm Eastern/1:30pm Pacific - Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced financial and operating results for the fourth quarter and full year ended December 31, 2018. "In just five years, we have provided more than half a million people with high quality, comprehensive, affordable genetic information to inform healthcare decisions across all stages of life," said Sean George, co-founder and chief executive officer of Invitae. "We believe we're on an unprecedented growth trajectory that translates into better health decisions informed by genetic information. Our seemingly audacious mission to bring genetics into mainstream medicine and benefit people through all stages of life, is coming into clear focus - not

February 13, 2019 Invitae to Present at the 8th Annual SVB Leerink Global Healthcare Conference

Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced that Sean George, co-founder and chief executive officer of Invitae, will present at the 8th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 27, 2019 at 11:30 a.m. Eastern / 8:30 a.m. Pacific in New York City. A live webcast of the presentation may be accessed by visiting the investors section of the company's website at ir.invitae.com . A replay of the webcast will be available shortly after the conclusion of the presentation and will be archived on the company's website. About Invitae Invitae Corporation (NYSE: NVTA) is a leading genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. For more information, visit the company's website at invitae.com.

February 12, 2019 Invitae Launches Non-Invasive Prenatal Screening (NIPS), Offering In-Depth Genetic Information in Early Pregnancy

- In Combination with Carrier Screening, NIPS Provides Affordable, Streamlined Access to Genetic Testing for Parents-to-Be - Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced the addition of non-invasive prenatal screening (NIPS) to the company's comprehensive women's health genetic testing services, providing patients with easier access to affordable genetic testing in early pregnancy. In combination with the expanded carrier screening (ECS), Invitae now offers integrated testing using the two most common prenatal genetic tests, with in-depth follow-up testing available for patients who need it. The company made the announcement in conjunction with the Society for Maternal-Fetal Medicine (SMFM) meeting in Las Vegas. "NIPS is an important advance in prenatal screening. Historically, access to NIPS has been restricted to high-risk patients, but established criteria are imperfect predictors. With affordable NIPS now available, all women can benefit from

February 7, 2019 New Study Finds Disease-Causing Variants More Common in Men with Prostate Cancer Than Previously Thought

- Largest Dataset of Prostate Cancer Patients Shows 17% Have Increased Risk Based on Genetic Analysis -
- Testing Guidelines Still Exclude At-Risk Patients - The largest study to date on the genetics of prostate cancer has found that 17 percent of prostate cancer patients are born with genetic variants that can be associated with higher risk of various cancers. The study was published today in JAMA Oncology by researchers from Tulane Cancer Center and Invitae (NYSE: NVTA), a leading genetics company. In addition, the analysis found that guidelines for genetic testing at the time of the study missed a substantial number of patients, suggesting broader testing is warranted. "This research shows the genetic risks associated with prostate cancer have been underestimated and provides support for expanding testing to include an increased number of prostate cancer patients," said Oliver Sartor, M.D., Tulane Cancer Center medical director and lead author on the study. "Expanding the

January 29, 2019 Invitae to announce fourth quarter and year-end 2018 financial results on February 19, 2019

Invitae Corporation (NYSE: NVTA), the fastest growing clinical genetics company, today announced that it will report its fourth quarter and year-end 2018 financial results on Tuesday, February 19, 2019 and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent developments. The dial-in numbers for the conference call are (866) 393-4306 for domestic callers and (734) 385-2616 for international callers, and the reservation number for both is 6799673. Following prepared remarks, management will respond to questions from investors and analysts, subject to time limitations. We encourage our shareholders and those representing them to send in questions to ir@invitae.com . The live webcast of the call may be accessed by visiting the investors section of the company's website at ir.invitae.com. A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the company's

January 7, 2019 Invitae reports 2018 preliminary financial results, delivering more than 100% volume and revenue growth in 2018; projects sustained growth in expanding markets through 2019 and beyond

- Delivered more than 302,000 samples, generating revenue of more than $144 million in 2018 -
- Provides 2019 guidance of more than 500,000 sample test volume and more than $220 million in 2019 revenue - Invitae Corporation (NYSE: NVTA), the fastest growing clinical genetics company, announced preliminary unaudited full-year 2018 results showing triple-digit growth driven by strong commercial execution, test menu expansion and the accelerating use of genetics in healthcare. "We envisioned a world in which genetic information can inform healthcare decisions throughout every stage of life, and that is rapidly becoming a reality. Invitae's strong 2018 results are indicative of this shift as we bring genetics into mainstream medicine with high-quality, comprehensive, affordable testing," said Sean George, co-founder and chief executive officer of Invitae. "With another year of unprecedented growth behind us, we intend to build on this momentum in 2019, growing an even larger network

Press releases

FORWARD-LOOKING STATEMENTS

Investor Contact